Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse

Condition(s) targeted: Malaria, Vivax

Intervention: Chloroquine 600mg (Drug); Chloroquine 300mg (Drug); Tafenoquine 50mg (Drug); Tafenoquine 100mg (Drug); Tafenoquine 300mg (Drug); Tafenoquine 600mg (Drug); Primaquine 15mg (Drug); Chloroquine 600mg (Part 2 ) (Drug); Chloroquine 300mg (Part 2 ) (Drug); Tafenoquine 300mg (Part 2) (Drug); Primaquine 15mg (Part2 ) (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline

Overall contact:
US GSK Clinical Call Center, Phone: 877-379-3718, Email: GSKClinicalSupportHD@gsk.com

The purpose of this two part study is to test the safety and efficacy of Tafenoquine (with Cholorquine) as a radical cure for Plasmodium vivax (P. vivax) malaria relative to the control Chloroquine. Part 1 aims to select an efficacious and well tolerated dose that can be co-administered with Chloroquine. Part 2 will investigate the safety and efficacy of the selected dose (300 mg tafenoquine) in the treatment and radical cure of Plasmodium Vivax Malaria.

Official title: A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Relapse Efficacy

Relapse-free efficacy (Part 2)

Secondary outcome:

Relapse Efficacy (Part 1)

Time to relapse

Parasite clearance time

Fever clearance time

Healthcare Impact (Part 2)

Relapse-free efficacy (Part 2)

Detailed description: Plasmodium vivax represents 50-80% of all malarial cases in Latin America and South East Asia. It is able to establish a dormant liver stage called the hypnozoite. Hypnozoite activation after initial infection can cause a relapse. Currently the only widely available drug is primaquine which requires administration over 14 days, resulting in poor compliance and treatment failure. Tafenoquine (an 8-aminoquinoline anti-malarial drug) has been shown to possess activity against all stages of the plasmodium life cycle, including the dormant stage in the liver. This is a multi-centre, double dummy, double blind, parallel group, randomized, active control study which is conducted in two parts. For both parts, subjects are treated with Chloroquine on days 1 to 3 (600mg, 600mg, and 300mg) to treat the blood stage vivax malaria. Part 1 will include at least 324 subjects and part 2 at least 600 subjects. Part 1 has 6 treatment arms, arms 1 to 4 contain different doses of Tafenoquine (50mg, 100mg, 300mg, and 600mg) dosed on day 1 or 2, arm 5 contains primaquine (15mg) dosing over 14 days (days 2-15 (15mg)) and arm 6 contains chloroquine only. The aim of this is to find a dose of Tafenoquine which meets the defined dose criteria. Based on Part 1 efficacy and safety, a single Tafenoquine dose (300 mg) will be studied in the pivotal Part 2. Part 2 contains 3 treatment arms one with the selected Tafenoquine dose (300 mg), the second arm will be 15mg Primaquine which will again be dosed over 14 days and the final arm contains chloroquine only dosed days 1-3 (600mg, 600mg, 300mg). Therefore as with Part 1, in Part 2 all subjects will receive Chloroquine. The aim of Part 2 is to investigate the safety and efficacy of the selected Tafenoquine/Chloroquine dose in the treatment and radical cure of Plasmodium vivax malaria. In addition to the Primary and Secondary endpoints stated below we will also be collecting; other efficacy endpoints (gametocyte clearance time, Recrudescence defined as any Plasmodium vivax parasitemia occurring on or before Day 29 (blood stage treatment failure), Incidence of Plasmodium falciparum malaria and Incidence of recrudescence and new Plasmodium vivax infection, determined by Polymerase Chain Reaction (PCR), safety endpoints (clinically relevant haemolysis leading to drops in haemoglobin / haematocrit or complications thereof (required transfusions, acute renal failure), changes

in methaemoglobin, gastrointestinal (GI) tolerability - incidence of abdominal pain,

heartburn, diarrhoea, constipation, nausea and vomiting and ophthalmic safety - incidence of

corneal deposits, retinal and visual field abnormalities. Data collected at up to four centres . Additionally, the incidence and severity of adverse events and abnormal laboratory observations will be presented).Pharmacokinetic endpoints (Population pharmacokinetic parameters for tafenoquine including but not limited to oral clearance (CL/F) and volume of distribution (V/F)and Pharmacokinetic/Pharmacodynamic endpoints (e. g. tafenoquine plasma concentrations) and selected Pharmacodynamic endpoints (e. g. relapse efficacy, change in methaemoglobin) if appropriate, will be explored.

Minimum age: 16 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: - Positive Giemsa smear for P. vivax

- Parasite density >100 and <200,000/μL

- ≥16 years

- A female is eligible if she is non-pregnant, nonlactating and if she is of: -

non-child bearing potential defined as: post-menopausal (12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone >40 mIU/mL), pre-menopausal and has had a hysterectomy or a bilateral oophorectomy (removal of the ovaries) or a bilateral tubal ligation with medical report verification, negative pregnancy test or,

- child-bearing potential, has a negative serum pregnancy test at screening, and agrees

to comply with one of the following during the treatment stage of the study and for a period of 90 days after stopping study drug:

- Use of oral contraceptive, either combined or progestogen alone used in conjunction

with double barrier method as defined below

- Use of an intrauterine device with a documented failure rate of <1% per year

- Use of depo provera injection (part 2)

- Double barrier method consisting of spermicide with either condom or diaphragm

- Male partner who is sterile prior to the female subject's entry into the study and is

the sole sexual partner for that female.

- Complete abstinence from intercourse for 2 weeks prior to administration of study

drug, throughout the study and for a period of 90 days after stopping study drug.

- A signed and dated informed consent is obtained from the subject or the subject's

legal representative prior to screening. NB Assent is obtained from subjects <18 years, where applicable and written or oral witnessed consent has been obtained from parent or guardian.

- The subject is able to understand and comply with protocol requirements, instructions

and protocol-stated restrictions and is likely to complete the study as planned.

- Willing to be hospitalized for 3 days and return to clinic for all follow-up visits

including Day 180

- QTc <450 msec at screening, based on a single QTcF value at screening (part 1 only)

or as an average of triplicate Electrocardiogram obtained over a brief recording

period by machine or manual over-read if first is >450 msec.- Exclusion Criteria: -

Mixed malaria infections (e. g. identified by Giemsa-stained smear or rapid diagnostic test)

- Severe vivax malaria as defined by World Health Organisation criteria.

- Severe vomiting (no food or inability to take food during previous 8 hours)

- Screening haemoglobin concentration <7 g/dL.

- Glucose 6-phosphate dehydrogenase deficiency, assessed by a quantitative

spectrophotometric phenotype assay:

Part 1 - Males: Any subject with an enzyme level <70% of the site median value for Glucose

6-phosphate dehydrogenase normals will be excluded. Females: Those females with a screening Hb ≥ 10 g/dL will only be excluded if their enzyme level is <70% of the site median value for Glucose 6-Phosphate dehydrogenase normals. hose females with Hb ≥7 but < 10 g/dL will be excluded if an enzyme level is not > 90% of the site median value for Glucose 6-Phosphate dehydrogenase normals.

Part 2 - Any subject with enzyme level <70% of the site median value for Glucose

6-phosphate dehydrogenase normals will be excluded

- Liver function test alanine transaminase >2x Upper Limit of Normal

- Any clinically significant concurrent illness (e. g. pneumonia, septicaemia),

pre-existing conditions (e. g. renal disease, malignancy), conditions that may affect absorption of study medication (e. g. vomiting or severe diarrhea) or clinical signs and symptoms of severe cardiovascular disease (e. g. uncontrolled congestive heart failure or severe coronary artery disease). These abnormalities may be identified on the screening history and physical or laboratory examination.

- Subject has taken antimalarials (e. g. ACT, mefloquine, primaquine, chloroquine) or

drugs with anti-malarial activity within the past 30 days by history.

- History of allergy to chloroquine, mefloquine, tafenoquine, primaquine or to any

other 4- or 8-aminoquinolines.

- Any contraindications to chloroquine or primaquine administration including a history

of porphyria, psoriasis or epilepsy (please refer to chloroquine and primaquine locally approved prescribing information).

- Subject who has previously received study medication for this protocol (all parts) or

has received treatment with any other investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.

- History of illicit drug abuse or heavy alcohol intake within 6 months of the study.

- Subjects who have taken or will likely require the use of medications from the

prohibited medication list which include the following classes: Histamine-2 blockers and antacids.

- Drugs with haemolytic potential.

- Drugs known to prolong the QTc interval

US GSK Clinical Call Center, Phone: 877-379-3718, Email: GSKClinicalSupportHD@gsk.com

GSK Investigational Site, Bandarban, Bangladesh; Terminated

GSK Investigational Site, Oddar Meancheay Province, Cambodia; Recruiting
US GSK Clinical Trials Call Center, Phone: 877-379-3718, Email: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center, Phone: +44 (0) 20 8990 4466, Email: GSKClinicalSupportHD@gsk.com

GSK Investigational Site, Bikaner, India; Completed

GSK Investigational Site, Chennai 600016, India; Completed

GSK Investigational Site, Lucknow 226003, India; Completed

GSK Investigational Site, Secunderabad 500 003, India; Completed

GSK Investigational Site, Rio Tuba, Bataraza 5306, Philippines; Recruiting
US GSK Clinical Trials Call Center, Phone: 877-379-3718, Email: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center, Phone: +44 (0) 20 8990 4466, Email: GSKClinicalSupportHD@gsk.com

GSK Investigational Site, Bangkok 10400, Thailand; Recruiting
US GSK Clinical Trials Call Center, Phone: 877-379-3718, Email: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center, Phone: +44 (0) 20 8990 4466, Email: GSKClinicalSupportHD@gsk.com

GSK Investigational Site, Tak 63110, Thailand; Completed

GSK Investigational Site, Manaus, Amazonas 69040-000, Brazil; Recruiting
US GSK Clinical Trials Call Center, Phone: 877-379-3718, Email: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center, Phone: +44 (0) 20 8990 4466, Email: GSKClinicalSupportHD@gsk.com

GSK Investigational Site, Iquitos, Loreto Iqui 01, Peru; Recruiting
US GSK Clinical Trials Call Center, Phone: 877-379-3718, Email: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center, Phone: +44 (0) 20 8990 4466, Email: GSKClinicalSupportHD@gsk.com

GSK Investigational Site, Porto Velho, Rondônia 76812-329, Brazil; Recruiting
US GSK Clinical Trials Call Center, Phone: 877-379-3718, Email: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center, Phone: +44 (0) 20 8990 4466, Email: GSKClinicalSupportHD@gsk.com

Starting date: September 2011
Last updated: April 20, 2015